Macrogenics reported $188.97M in Cash and Equivalent for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Amgen AMGN:US $ 6630M 518M
AstraZeneca AZN:LN 15567M 7931M
Biogen BIIB:US $ 1541.8M 200.2M
Bristol Myers Squibb BMY:US $ 11024M 42M
Cerulean Pharma CERU:US $ 9.11M 1.45M
Daiichi Sankyo 4568:JP Y 352262M 28285M
Dicerna Pharmaceuticals DRNA:US $ 221.21M 62.1M
Eli Lilly And LLY:US $ 3220M 217.6M
Epizyme EPZM:US $ 80.16M 6.45M
Genmab GEN:DC DK 9477M 1585M
Geron GERN:US $ 57.64M 26.11M
Gilead Sciences GILD:US $ 7361M 3296M
Immunogen IMGN:US $ 239.54M 43.58M
Karyopharm Therapeutics KPTI:US $ 141.31M 52.84M
Macrogenics MGNX:US $ 188.97M 29.53M
Mirati Therapeutics MRTX:US $ 258.99M 35.9M
Puma Biotechnology PBYI:US $ 89.85M 5.8M
Regeneron Pharmaceuticals REGN:US $ 2072.2M 634.3M
Seattle Genetics SGEN:US $ 413.43M 39.72M
Xencor XNCR:US $ 115.84M 61.12M